胰高血糖素受体拮抗剂I | 438618-32-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 胰高血糖素受体拮抗剂I
• 英文名称: N-(3-cyano-6-(1,1-dimethylpropyl)-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-ethylbutanamide
• 英文别名: N-[3-cyano-6-(1,1-dimethylpropyl)-4,5,6,7-tetrahydro-1-benzothien-2-yl]-2-ethylbutanamide；GCGR antagonist I；Glucagon Receptor Antagonist I；N-[3-cyano-6-(2-methylbutan-2-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]-2-ethylbutanamide
• CAS: 438618-32-7
• 化学式: C₂₀H₃₀N₂OS
• 分子量: 346.537
• InChiKey: SWIBDWBSJSJQHL-UHFFFAOYSA-N

物化性质

• 沸点：
  517.8±50.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  81.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-叔丁基环己酮 在 吗啉 、 1,2,3,4,5,6,7,8-八硫杂环辛烷 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 胰高血糖素受体拮抗剂I
  参考文献：
  名称：

  Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor

  摘要：

  A novel class of antagonists of the human glucagon receptor (bGCGR) has been discovered. Systematic modification of the lead compound identified substituents that were essential for activity and those that were amenable to further optimization. This SAR exploration resulted in the synthesis of 13, which exhibited good potency as an hGCGR functional antagonist (IC50 = 34 nM) and moderate bioavailability (36% in mice). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.003

文献信息

• Method of treating diabetes and related conditions
  申请人：Duffy Joseph

  公开号：US20060035958A1

  公开（公告）日：2006-02-16

  The present invention addresses the use of substituted thiophene derivatives, as well as compositions containing such compounds for treating type 2 diabetes mellitus. The compounds in the present invention are glucagon antagonists. The compounds block the action of glucagon at its receptor and thereby decrease the levels of plasma glucose providing a treatment of diabetes.

  本发明涉及使用取代噻吩衍生物以及含有这些化合物的组合物来治疗2型糖尿病。本发明中的化合物是胰高血糖素拮抗剂。这些化合物阻止胰高血糖素在其受体上的作用，从而降低血浆葡萄糖水平，提供糖尿病治疗。
• Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor
  作者：Joseph L. Duffy、Brian A. Kirk、Zenon Konteatis、Elizabeth L. Campbell、Rui Liang、Edward J. Brady、Mari Rios Candelore、Victor D.H. Ding、Guoqiang Jiang、Frank Liu、Sajjad A. Qureshi、Richard Saperstein、Deborah Szalkowski、Sharon Tong、Lauri M. Tota、Dan Xie、Xiaodong Yang、Peter Zafian、Song Zheng、Kevin T. Chapman、Bei B. Zhang、James R. Tata

  DOI：10.1016/j.bmcl.2005.01.003

  日期：2005.3

  A novel class of antagonists of the human glucagon receptor (bGCGR) has been discovered. Systematic modification of the lead compound identified substituents that were essential for activity and those that were amenable to further optimization. This SAR exploration resulted in the synthesis of 13, which exhibited good potency as an hGCGR functional antagonist (IC50 = 34 nM) and moderate bioavailability (36% in mice). (c) 2005 Elsevier Ltd. All rights reserved.
• METHOD OF TREATING DIABETES AND RELATED CONDITIONS
  申请人：Merck & Co., Inc.

  公开号：EP1538903A2

  公开（公告）日：2005-06-15
• COMPOUNDS AND METHODS FOR TREATING GASTROINTESTINAL DISEASE
  申请人：The Regents of the University of California

  公开号：EP3856720A1

  公开（公告）日：2021-08-04
• [EN] METHOD OF TREATING DIABETES AND RELATED CONDITIONS<br/>[FR] METHODE DE TRAITEMENT DU DIABETE ET D'ETATS ASSOCIES
  申请人：MERCK & CO INC

  公开号：WO2004024066A2

  公开（公告）日：2004-03-25

  The present invention addresses the use of substituted thiophene derivatives, as well as compositions containing such compounds for treating type 2 diabetes mellitus. The compounds in the present invention are glucagon antagonists. The compounds block the action of glucagon at its receptor and thereby decrease the levels of plasma glucose providing a treatment of diabetes.